Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Jaehyun BaeBong Soo Cha

Abstract

Comparisons of the glycemic durability between thiazolidinediones (TZDs) and dipeptidyl peptidase-4 (DPP-4) inhibitors remain insufficient. This study aimed to find clues for the differences in glycemic durability between TZDs and DPP-4 inhibitors by comparing the insulin resistance and β-cell function among patients using these agents. A total of 241 patients with type 2 diabetes mellitus (T2DM) treated with either pioglitazone (a TZD) or DPP-4 inhibitors as combination therapy with metformin for at least 1 year were analyzed. A propensity score based on the patients' baseline characteristics and glycated hemoglobin (HbA1c) was used to match them. Indices for insulin resistance and secretory function of β-cells, namely the homeostasis model assessment of insulin resistance (HOMA-IR) or β-cells (HOMA-β), were calculated and compared. Multiple regression analysis was performed to find the independent variables correlated with β-cell function or insulin resistance. Evaluation of the data from 168 matched patients with T2DM showed that TZD users had significantly better insulin sensitivity compared with DPP-4 inhibitor users (HOMA-IR 2.3 ± 1.9 vs. 3.5 ± 3.2, p = 0.003). Conversely, DPP-4 inhibitor users secreted more insulin than ...Continue Reading

References

May 27, 2004·Diabetes Care·Tara M WallaceDavid R Matthews
Nov 1, 2006·International Journal of Clinical Practice·A Barnett
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Apr 22, 2008·Expert Opinion on Pharmacotherapy·C V RizosM S Elisaf
Oct 30, 2008·The Journal of Clinical Endocrinology and Metabolism·David A D'AlessioRichard E Pratley
May 12, 2010·International Journal of Clinical Practice·T SeckUNKNOWN Sitagliptin Study 024 Group
May 2, 2013·The Journal of Clinical Endocrinology and Metabolism·Payal ShahKathrin Maedler
Jun 29, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Sung-Chen LiuChing-Hsiang Leung
Jan 7, 2015·Pharmacological Reports : PR·Agnieszka StrózikBogusław Okopień
Jul 28, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Giuseppe DerosaPamela Maffioli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.